Loading..

Agios Pharmaceuticals, Inc. (AGIO) Report Analysis

Corporate Events

Positive

Centogene N.V. and Agios Pharmaceuticals, Inc. ...

2022-06-13 10:30:00

Centogene N.V. announced that it has expanded its long-standing PYRUKYND® (mitapivat) partnership with Agios Pharmaceuticals, Inc. Agios’ PYRU...

Positive

Agios Presents New Clinical Data Supporting the...

2022-06-10 14:30:00

Agios Pharmaceuticals, Inc. reported new data further underscoring the significant burden of disease in adults with pyruvate kinase deficiency...

Neutral

Agios Pharmaceuticals, Inc. - Special Call

2022-06-10 14:30:00

To review select data from the EHA presentations

Neutral

Agios Pharmaceuticals, Inc. Presents at DGE's 2...

2022-06-01 11:06:00

Agios Pharmaceuticals, Inc. Presents at DGE's 2nd KOL & Thought Leader Engagement Summit, Jun-01-2022 09:15 AM. Speakers: Gaurav Sharma, Sr. D...

Neutral

Dynamic Global Events LLC, DGE's 2nd KOL & Thou...

2022-06-01 10:15:00

Dynamic Global Events LLC, DGE's 2nd KOL & Thought Leader Engagement Summit, Jun 01, 2022 through Jun 02, 2022.

Negative

Agios Pharmaceuticals, Inc. Announces Resignati...

2022-05-26 20:06:00

On May 23, 2022, Agios Pharmaceuticals, Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with Bruce Car, ...

Neutral

Agios Pharmaceuticals, Inc. Presents at Europea...

2022-05-26 00:00:00

Agios Pharmaceuticals, Inc. Presents at European Hematology Association 2022 Annual Congress, Jun-09-2022 through Jun-17-2022. Venue: Vienna, ...

Negative

Agios Pharmaceuticals, Inc. Announces Managemen...

2022-05-16 20:15:00

Agios Pharmaceuticals, Inc. announced the evolution of its research organization. Sarah Gheuens, M.D., Ph.D., the company’s current chief medi...

Neutral

Agios Pharmaceuticals, Inc. Presents at RBC Cap...

2022-05-10 11:00:00

Agios Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-17-2022 10:30 AM. Venue: InterContinental New Yo...

Neutral

The European Hematology Association, European H...

2022-05-10 11:00:00

The European Hematology Association, European Hematology Association 2022 Annual Congress, Jun 09, 2022 through Jun 17, 2022. Venue: Vienna, Austria.

Neutral

Tranche Update on Agios Pharmaceuticals, Inc. (...

2022-05-05 09:47:00

From January 1, 2022 to March 31, 2022, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has compl...

Negative

Agios Pharmaceuticals, Inc. Announces Resignati...

2022-04-26 20:02:00

On April 25, 2022, Ian T. Clark notified Agios Pharmaceuticals, Inc. of his decision to resign as a member of the Board, effective immediately...

Neutral

Agios Pharmaceuticals, Inc., Q1 2022 Earnings C...

2022-04-21 11:00:00

Agios Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

Agios Pharmaceuticals, Inc. to Report Q1, 2022 ...

2022-04-21 11:00:00

Agios Pharmaceuticals, Inc. announced that they will report Q1, 2022 results on May 05, 2022

Neutral

RBC Capital Markets, LLC, RBC Capital Markets G...

2022-03-04 01:06:00

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022. Venue: InterContinental New Yor...

Neutral

Tranche Update on Agios Pharmaceuticals, Inc. (...

2022-02-24 11:34:00

From October 1, 2021 to December 31, 2021, the company has repurchased 416,259 shares, representing 0.76% for $19.05 million. With this, the c...

Neutral

Agios Pharmaceuticals, Inc., Annual General Mee...

2022-01-14 21:02:00

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 21, 2022, at 09:00 US Eastern Standard Time. Agenda: To elect each of the three Class...

Neutral

Agios Pharmaceuticals, Inc. - Shareholder/Analyst Call

2022-01-14 21:02:00

AGM

Positive

Agios Pharmaceuticals, Inc. Presents Mitapivat ...

2021-12-13 23:15:00

Agios Pharmaceuticals, Inc. reported new data from the ongoing long-term extension study assessing the duration of effects of mitapivat on hem...

Positive

Agios Pharmaceuticals, Inc. Presents Mitapivat ...

2021-12-13 15:30:00

Agios Pharmaceuticals, Inc. reported data for the first time from the ongoing long-term extension period of the Phase 2 open-label study of mi...

Positive

Agios Pharmaceuticals, Inc. Announces Data from...

2021-12-13 12:00:00

Agios Pharmaceuticals, Inc. announced new data from investigator-led studies of mitapivat, a first-in-class, investigational, oral, small mole...

Negative

Agios Pharmaceuticals, Inc. Announces Executive Changes

2021-11-15 21:01:00

Agios Pharmaceuticals, Inc. announced the appointment of Richa Poddar to the role of chief commercial officer, effective Dec. 6, 2021. Ms. Pod...

Neutral

Agios Pharmaceuticals, Inc. Presents at 63rd Am...

2021-11-04 13:15:00

Agios Pharmaceuticals, Inc. Presents at 63rd American Society of Hematologists Annual Meeting & Exposition, Dec-11-2021 through Dec-15-2021. V...

Neutral

Agios Pharmaceuticals, Inc. - Special Call

2021-11-04 13:15:00

To review the key clinical oral and poster presentations

Neutral

CENTOGENE Expands Partnership with Agios to Gen...

2021-11-04 10:30:00

Centogene N.V. announced that it has expanded its partnership with Agios Pharmaceuticals, Inc. Under the terms of the new agreement, CENTOGENE...

Neutral

Tranche Update on Agios Pharmaceuticals, Inc. (...

2021-11-03 13:09:00

From July 1, 2021 to September 30, 2021, the company has repurchased 5,306,184 shares, representing 8.86% for $254.38 million. With this, the ...

Neutral

Agios Pharmaceuticals, Inc. - Analyst/Investor Day

2021-11-03 11:10:00

To discuss the company’s research and development pipeline, as well as provide additional insights into the commercial launch strategy and exp...

Neutral

Agios Pharmaceuticals, Inc., Q3 2021 Earnings C...

2021-10-21 20:01:00

Agios Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Agios Pharmaceuticals, Inc. Presents at 10th An...

2021-09-15 13:42:00

Agios Pharmaceuticals, Inc. Presents at 10th Annual Sickle Cell Disease Therapeutics Conference, Sep-15-2021 01:50 PM. Speakers: Sarah Gheuens...

Neutral

Global Blood Therapeutics, Inc., Sickle Cell Di...

2021-09-08 21:05:00

Global Blood Therapeutics, Inc., Sickle Cell Disease Association of America, Inc., 10th Annual Sickle Cell Disease Therapeutics Conference, S...

Neutral

Agios Pharmaceuticals, Inc. Presents at Citi’s ...

2021-08-30 11:00:00

Agios Pharmaceuticals, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-10-2021 12:30 PM. Venue: New York, United States....

Neutral

Agios Pharmaceuticals, Inc. Presents at Cantor ...

2021-08-30 11:00:00

Agios Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 08:00 AM. Venue: New York, United States. Speake...

Neutral

Sickle Cell Advocacy, 8th Annual Sickle Cell Wa...

2021-08-20 12:44:00

Sickle Cell Advocacy, 8th Annual Sickle Cell Warriors Convention, Aug 25, 2021 through Aug 29, 2021.

Positive

Agios Pharmaceuticals, Inc. Announces FDA Accep...

2021-08-17 20:01:00

Agios Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) f...

Negative

Agios Pharmaceuticals, Inc. Announces Executive Changes

2021-08-04 20:36:00

On August 1, 2021, Agios Pharmaceuticals, Inc. (the 'Company') appointed T.J. Washburn, senior director, corporate accounting of the Company, ...

Neutral

American Society Of Hematology, 63rd American S...

2021-07-31 11:04:00

American Society Of Hematology, 63rd American Society of Hematologists Annual Meeting & Exposition, Dec 11, 2021 through Dec 15, 2021. Venue: ...

Negative

Agios Pharmaceuticals, Inc. Announces Executive Changes

2021-07-29 11:00:00

Agios Pharmaceuticals, Inc. announced succession plan for Chris Bowden, M.D., who will transition from his role as chief medical officer to st...

Neutral

Tranche Update on Agios Pharmaceuticals, Inc. (...

2021-07-29 10:57:00

From April 1, 2021 to June 30, 2021, the company has repurchased 10,493,968 shares, representing 15.03% for $529 million. With this, the compa...

Neutral

Agios Pharmaceuticals, Inc. to Report Q2, 2021 ...

2021-07-27 21:27:00

Agios Pharmaceuticals, Inc. announced that they will report Q2, 2021 results on Jul 29, 2021

Neutral

Agios Pharmaceuticals, Inc., Q2 2021 Earnings C...

2021-07-15 11:00:00

Agios Pharmaceuticals, Inc., Q2 2021 Earnings Call, Jul 29, 2021

Positive

Centogene N.V. and Agios Pharmaceuticals, Inc. Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children with Rare Blood Disease

2022-06-13 10:30:00

Centogene N.V. announced that it has expanded its long-standing PYRUKYND® (mitapivat) partnership with Agios Pharmaceuticals, Inc. Agios’ PYRUKYND® is a first-in-class, selective, small molecule activator of the pyruvate kinase (PK) enzyme. In February 2022, Agios received approval from the U.S. Food and Drug Administration (FDA) for PYRUKYND® for the treatment of hemolytic anemia in adults with PK deficiency, which represents the first and only approved disease-modifying treatment for this rare blood disorder. Since 2015, CENTOGENE has provided genetic testing services to Agios for the clinical development of PYRUKYND®. The expanded agreement will now see CENTOGENE provide centralized lab support for Agios’ two global, pivotal Phase 3 trials, ACTIVATE-kids and ACTIVATE-kidsT, which are being conducted to evaluate the efficacy and safety of mitapivat in children with PK deficiency between the ages of 1 to 17. CENTOGENE will continue to provide genetic testing to help identify causative mutations, including the UGT1A1 and PKLR genes, in study participants. The aim of the Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies is to test the efficacy of PYRUKYND® in pediatric patients with PK deficiency who do not receive regular transfusions and those who do receive regular transfusions, respectively. Agios will be coordinating and bearing the costs for the programs; other financial details were not disclosed. Within the partnership, CENTOGENE’s proprietary CentoCard® dried blood spot technology provides easy logistics for central diagnostic testing. Key assets to the partnership include the CENTOGENE Biodatabank, diagnostic expertise built on over 15 years of experience, and the Company’s multiomic-based platform, which is pioneering access to commercial multiomic products on the market.

Positive

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

2022-06-10 14:30:00

Agios Pharmaceuticals, Inc. reported new data further underscoring the significant burden of disease in adults with pyruvate kinase deficiency regardless of genotype and supporting the potential benefits of treatment with PYRUKYND® for these patients. Data are being presented at the European Hematology Association Annual Congress, hosted virtually and in person in Vienna on June 9-12, 2022. PYRUKYND® was approved in February 2022 by the U.S. Food and Drug Administration (FDA) for the treatment of hemolytic anemia in adults with PK deficiency. PYRUKYND® is also under review by the European Medicines Agency as a potential treatment for adults with PK deficiency, and Agios expects a regulatory decision in the EU by the end of 2022. Both the FDA and EMA have granted orphan drug designation to PYRUKYND® in PK deficiency. This analysis of data from the Phase 3 ACTIVATE study and the ongoing long-term extension study assessed the proportion of patients who achieved normal hemoglobin levels, as defined by central and local laboratory manuals, at least once while receiving PYRUKYND® without requiring any transfusions. Data demonstrate that treatment with PYRUKYND® was associated with normalization of hemoglobin levels. A greater proportion of patients achieved normalization of hemoglobin levels among the subset who met the primary endpoint as hemoglobin responders, defined as a hemoglobin increase of =1.5 g/dL at =2 scheduled assessments at weeks 16, 20 and 24 during the fixed-dose period. As of the September 21, 2021 data cut-off, 40/40 patients in the mitapivat arm and 38/40 patients in the placebo crossover arm continued treatment in the extension study. Results were as follows: Across the ACTIVATE and extension studies, 28/78 (35.9%) of all patients achieved a normal hemoglobin level at least once during treatment with PYRUKYND® Among hemoglobin endpoint responders, 26/31 (83.9%) achieved a normal hemoglobin level at least once while receiving treatment with mitapivat. The majority of patients who achieved a normal hemoglobin level at least once in the ACTIVATE and extension studies achieved their first normal hemoglobin level within four months of treatment with PYRUKYND®.

Neutral

Agios Pharmaceuticals, Inc. - Special Call

2022-06-10 14:30:00

To review select data from the EHA presentations

Neutral

Agios Pharmaceuticals, Inc. Presents at DGE's 2nd KOL & Thought Leader Engagement Summit, Jun-01-2022 09:15 AM

2022-06-01 11:06:00

Agios Pharmaceuticals, Inc. Presents at DGE's 2nd KOL & Thought Leader Engagement Summit, Jun-01-2022 09:15 AM. Speakers: Gaurav Sharma, Sr. Director, Head of Global MSLs.

Neutral

Dynamic Global Events LLC, DGE's 2nd KOL & Thought Leader Engagement Summit, Jun 01, 2022 through Jun 02, 2022

2022-06-01 10:15:00

Dynamic Global Events LLC, DGE's 2nd KOL & Thought Leader Engagement Summit, Jun 01, 2022 through Jun 02, 2022.

Negative

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

2022-05-26 20:06:00

On May 23, 2022, Agios Pharmaceuticals, Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with Bruce Car, Ph.D., effective as of August 1, 2022 (the “Effective Date”), which is the date following the effective date of Dr. Car’s resignation as the Company’s chief scientific officer. Pursuant to the Consulting Agreement, Dr. Car has agreed to assist the Company with the transition of the research and discovery science and to provide such other services as may be requested by the Company from time to time (which services will not exceed 10 hours per week).

Neutral

Agios Pharmaceuticals, Inc. Presents at European Hematology Association 2022 Annual Congress, Jun-09-2022 through Jun-17-2022

2022-05-26 00:00:00

Agios Pharmaceuticals, Inc. Presents at European Hematology Association 2022 Annual Congress, Jun-09-2022 through Jun-17-2022. Venue: Vienna, Austria. Presentation Date(s): Jun-10-2022. Jun-11-2022.

Negative

Agios Pharmaceuticals, Inc. Announces Management Changes

2022-05-16 20:15:00

Agios Pharmaceuticals, Inc. announced the evolution of its research organization. Sarah Gheuens, M.D., Ph.D., the company’s current chief medical officer, will assume the role of head of research and development and chief medical officer at the end of July. Agios’ chief scientific officer, Bruce Car, Ph.D., will step down from the role and remain with the company through effective July 31, 2022 to facilitate the transition. In parallel, Agios is evolving its approach to exploratory research and drug discovery to focus on its existing late lead-optimization programs and leverage business development opportunities to complement these programs and ensure a sustainable pipeline. Agios plans to reduce up to 50 roles focused on exploratory research, while retaining a strong internal research team focused on roles critical to advancing the company’s current and future late-stage research and early clinical programs. The initiative is expected to deliver annual average cost savings of $40-50 million associated with research and related expenses between 2023 and 2026.

Neutral

Agios Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-17-2022 10:30 AM

2022-05-10 11:00:00

Agios Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-17-2022 10:30 AM. Venue: InterContinental New York, Barclay hotel, New York, New York, United States.

Neutral

The European Hematology Association, European Hematology Association 2022 Annual Congress, Jun 09, 2022 through Jun 17, 2022

2022-05-10 11:00:00

The European Hematology Association, European Hematology Association 2022 Annual Congress, Jun 09, 2022 through Jun 17, 2022. Venue: Vienna, Austria.

Neutral

Tranche Update on Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO)'s Equity Buyback Plan announced on March 25, 2021.

2022-05-05 09:47:00

From January 1, 2022 to March 31, 2022, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 16,216,411 shares, representing 24.65% for $802.43 million under the buyback announced on March 25, 2021.

Negative

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

2022-04-26 20:02:00

On April 25, 2022, Ian T. Clark notified Agios Pharmaceuticals, Inc. of his decision to resign as a member of the Board, effective immediately following the 2022 annual meeting of stockholders. Mr. Clark will also resign as a member of the Company’s Compensation & People Committee and Nominating and Corporate Governance Committee. Mr. Clark informed the Company that his resignation was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.

Neutral

Agios Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022

2022-04-21 11:00:00

Agios Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

2022-04-21 11:00:00

Agios Pharmaceuticals, Inc. announced that they will report Q1, 2022 results on May 05, 2022

Neutral

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022

2022-03-04 01:06:00

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022. Venue: InterContinental New York, Barclay hotel, New York, New York, United States.

Neutral

Tranche Update on Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO)'s Equity Buyback Plan announced on March 25, 2021.

2022-02-24 11:34:00

From October 1, 2021 to December 31, 2021, the company has repurchased 416,259 shares, representing 0.76% for $19.05 million. With this, the company has completed the repurchase of 16,216,411 shares, representing 24.65% for $802.43 million under the buyback announced on March 25, 2021.

Neutral

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 21, 2022

2022-01-14 21:02:00

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 21, 2022, at 09:00 US Eastern Standard Time. Agenda: To elect each of the three Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2025 annual meeting of stockholders and until his or her respective successor is duly elected and qualified; to vote, on an advisory basis, to approve the compensation paid to the Company's named executive officers; to hold an advisory vote on the frequency of future advisory votes on the compensation paid to the Company's named executive officers; to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022; and to transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.

Neutral

Agios Pharmaceuticals, Inc. - Shareholder/Analyst Call

2022-01-14 21:02:00

AGM

Positive

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

2021-12-13 23:15:00

Agios Pharmaceuticals, Inc. reported new data from the ongoing long-term extension study assessing the duration of effects of mitapivat on hemoglobin response and transfusion burden reduction in adults with pyruvate kinase (PK) deficiency who had participated in one of the pivotal studies, ACTIVATE and ACTIVATE-T, conducted in not regularly transfused and regularly transfused adults with PK deficiency, respectively. Data from the study were featured in an oral presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition, hosted virtually and in person from Dec. 11-14, 2021, in Atlanta. Mitapivat is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase enzymes. Long-term extension data (abstract #848) demonstrate that previously reported effects of mitapivat on hemoglobin and transfusion burden were maintained over time. Non-regularly transfused patients randomized to mitapivat in ACTIVATE maintained hemoglobin response for up to 19.5 months. Similarly, 35% of ACTIVATE patients who switched from placebo to mitapivat in the extension study achieved a hemoglobin response, which was maintained for the duration of follow-up. All regularly transfused patients who achieved transfusion-free status in ACTIVATE-T with mitapivat treatment maintained the status through the extension study for up to 21.9 months. Mitapivat was well tolerated, and the safety profile was consistent with the core period of ACTIVATE and ACTIVATE-T, as well as previous studies. In addition, Agios presented data at ASH further supporting the potential of mitapivat to address hallmark symptoms and complications of PK deficiency. Mitapivat Improves Ineffective Erythropoiesis and Reduces Iron Overload in Patients with Pyruvate Kinase Deficiency (Abstract #757) In an oral presentation, data from ACTIVATE, ACTIVATE-T and the Phase 3 long-term extension study were reported, showing that treatment with mitapivat improved markers of ineffective erythropoiesis and iron metabolism in adults with PK deficiency, regardless of transfusion status. Through this mechanism, mitapivat may have the potential to improve iron homeostasis, thereby reducing iron overload. Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-term Treatment with Mitapivat (Abstract #924) In a separate poster presentation, data from a large, pooled analysis of the DRIVE-PK Phase 2 study, ACTIVATE and ACTIVATE-T Phase 3 studies and the Phase 3 long-term extension study were reported, assessing the impact of mitapivat treatment on bone mineral density in a broad population of non-regularly transfused and regularly transfused adults with PK deficiency for up to 5.5 years. Among the 64 patients who had low bone mineral density at baseline, 62 patients remained stable or improved while being treated with mitapivat.

Positive

Agios Pharmaceuticals, Inc. Presents Mitapivat Data Highlighting Long-Term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-Transfusion-Dependent A- and ß-Thalassemia At 63Rd Ash Annual Meeting and Exposition

2021-12-13 15:30:00

Agios Pharmaceuticals, Inc. reported data for the first time from the ongoing long-term extension period of the Phase 2 open-label study of mitapivat, a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase (PK) enzymes, in adults with non-transfusion dependent a- or ß-thalassemia. Data from the study were featured in an oral presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition, hosted virtually and in person from Dec. 11-14, 2021, in Atlanta. Consistent with previously reported data, durable improvements in hemoglobin concentration and markers of hemolysis and ineffective erythropoiesis, were observed for up to 72 weeks of treatment in both a- and ß-thalassemia patients. Mitapivat was well tolerated, and the safety profile was consistent with previous studies. Long-term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-transfusion-dependent Alpha- or Beta-Thalassemia (Abstract #576)The open-label Phase 2 study evaluated the efficacy, safety, pharmacokinetics and pharmacodynamics of mitapivat treatment in adults with either non-transfusion-dependent a- or ß-thalassemia who have a baseline hemoglobin concentration of =10 g/dL. The trial enrolled 20 patients. All patients were treated with an initial dose of 50 mg mitapivat twice daily followed by a dose-level increase to 100 mg twice daily at the Week 6 visit based on safety evaluations and hemoglobin concentrations. Following the completion of the 24-week core period, patients had the opportunity to enroll in an optional 10-year extension period to evaluate long-term efficacy and safety of mitapivat in this population. As of the data cut-off date of March 27, 2021, 17 of the 20 patients remain in the extension phase with a median treatment duration of 70.9 weeks (range 54.7-105.6). As of the data cut-off, efficacy results were as follows: Mean hemoglobin increase from baseline to Week 60 (a-thalassemia, n = 4; ß-thalassemia, n = 9) was 1.5 g/dL; Mean hemoglobin increase from baseline to Week 72 (ß-thalassemia, n = 8) was 1.7 g/dL; Improvements in markers of hemolysis and ineffective erythropoiesis achieved during the core period were sustained among both a- and ß-thalassemia patients, up to Week 72; Adverse events (AEs) for patients who continued in the study (n=17) were comparable in the core and extension periods. No new safety signals were identified in the extension period.

Positive

Agios Pharmaceuticals, Inc. Announces Data from Investigator-Led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at Ash Annual Meeting and Exposition

2021-12-13 12:00:00

Agios Pharmaceuticals, Inc. announced new data from investigator-led studies of mitapivat, a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase enzymes, in adults with sickle cell disease. The data, reported by the National Institutes of Health and University Medical Center Utrecht, were featured in two presentations at the American Society of Hematology Annual Meeting and Exposition, hosted virtually and in person from December 11-14, 2021, in Atlanta. The data demonstrate the potential of mitapivat to provide clinically meaningful outcomes for patients, including improvements in anemia, hemolysis and red blood cell sickling. Consistent with previously reported proof-of-concept data, mitapivat reduced 2,3-diphosphoglycerate and increased adenosine triphosphate, and through this mechanism, may reduce hemoglobin S polymerization and red blood cell sickling. The safety profile observed in both studies was also generally consistent with previously published clinical data, including Phase 3 data in adults with pyruvate kinase deficiency. The Phase 2 ESTIMATE study being conducted by UMC Utrecht is designed to assess safety and efficacy of mitapivat in patients with sickle cell disease. The primary endpoints of the study are safety and point of sickling, and key secondary endpoints include changes in hemoglobin levels and clinical complication rates. Key findings from six patients who completed the eight-week dose-finding period, all reaching 100 mg twice daily dosing, include: No serious adverse events occurred, and all AEs were mild and mostly transient. One vaso-occlusive crisis occurred without hospital admission and did not require dose reduction or discontinuation. All six patients had improvements in point of sickling. Observed changes in 2,3-DPG and ATP levels were consistent with proposed mechanism of action. Mitapivat increased hemoglobin and decreased hemolysis and sickling parameters. Five out of six patients achieved hemoglobin response. Early improvements in albumin-to-creatinine ratio were observed. Follow-up data from the ongoing study will be reported at a later stage. The Phase 1 study, which is being conducted in collaboration with the NIH as part of a cooperative research and development agreement, is designed to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of treatment with mitapivat in adults with sickle cell disease. The primary endpoint of the study is safety and tolerability, as assessed by frequency and severity of AEs and laboratory parameters. Secondary endpoints include changes in hemoglobin, markers of hemolysis, 2,3-DPG and ATP levels and hemoglobin S polymerization. Key findings from the 16 evaluable patients who completed the core period of the study, including up to eight weeks of dose escalation, dose taper and four-week safety follow-up, include: No AEs led to drug discontinuation. No VOCs occurred during dose-escalation. Two VOCs occurred during drug taper, which were deemed possibly drug-related, and two VOCs occurred during the 28-day safety follow-up. Treatment with mitapivat demonstrated improvement in anemia and decreases in markers of hemolysis, including lactate dehydrogenase, total bilirubin, absolute reticulocyte count and aspartate aminotransferase. Nine out of 16 patients achieved a hemoglobin response. Mitapivat reduced 2,3-DPG and increased ATP, with expected increase in oxygen affinity and decreased sickling rate. Long-term disease modifying effects being evaluated in an ongoing extension study. The Phase 2/3 RISE UP study will evaluate the efficacy and safety of mitapivat in sickle cell disease patients who are 16 years of age or older, have had between two and 10 sickle cell pain crises in the past 12 months, and have hemoglobin within the range of 5.5 to 10.5 g/dL during screening. The Phase 2 portion, which was recently initiated, includes a 12-week randomized, placebo-controlled period in which participants will be randomized in a 1:1:1 ratio to receive 50 mg mitapivat twice daily, 100 mg mitapivat twice daily or matched placebo. The primary endpoints are hemoglobin response, defined as =1 g/dL increase in average hemoglobin concentration from Week 10 through Week 12 compared to baseline, and safety. These data will be used to establish a clear dosing paradigm for the Phase 3 portion. The Phase 3 portion includes a 52-week randomized, placebo-controlled period in which participants will be randomized in a 2:1 ratio to receive the recommended mitapivat dose level or placebo. The primary endpoints are hemoglobin response, defined as =1 g/dL increase in average hemoglobin from baseline to Week 52, and annualized rate of sickle cell pain crises. Participants who complete either the Phase 2 or Phase 3 portion will have the option to move into a 216-week open-label extension period to receive mitapivat.

Negative

Agios Pharmaceuticals, Inc. Announces Executive Changes

2021-11-15 21:01:00

Agios Pharmaceuticals, Inc. announced the appointment of Richa Poddar to the role of chief commercial officer, effective Dec. 6, 2021. Ms. Poddar will replace Darrin Miles, who currently serves as the company’s chief commercial officer and has been with Agios since 2015. Mr. Miles will depart the company to pursue a chief executive officer role at a private biotechnology company.

Neutral

Agios Pharmaceuticals, Inc. Presents at 63rd American Society of Hematologists Annual Meeting & Exposition, Dec-11-2021 through Dec-15-2021

2021-11-04 13:15:00

Agios Pharmaceuticals, Inc. Presents at 63rd American Society of Hematologists Annual Meeting & Exposition, Dec-11-2021 through Dec-15-2021. Venue: Georgia World Congress Center, Atlanta, Georgia, United States. Presentation Date(s): Dec-13-2021.

Neutral

Agios Pharmaceuticals, Inc. - Special Call

2021-11-04 13:15:00

To review the key clinical oral and poster presentations

Neutral

CENTOGENE Expands Partnership with Agios to Generate Novel Insights into Rare Blood Diseases

2021-11-04 10:30:00

Centogene N.V. announced that it has expanded its partnership with Agios Pharmaceuticals, Inc. Under the terms of the new agreement, CENTOGENE will provide genetic testing and clinical trial support for Agios’ three global, pivotal trials in thalassemia and sickle cell disease. Under a previous agreement, CENTOGENE provided support for Agios’ pyruvate kinase (“PK”) deficiency clinical program. The Companies signed a commercial three-year fee-for-service agreement. Agios will be coordinating and bearing the costs for the programs. This collaboration will offer patients access to genetic testing to help identify causative mutations, including HBA1, HBA2, and HBB genes. Agios’ global clinical trials will enroll patients in North America, Europe, MENA, APAC, and LATAM. Samples will be collected using CENTOGENE’s proprietary CentoCard® for dried blood spot analysis. A key asset to the partnership is CENTOGENE’s unique rare disease-centric Bio/Databank, which is positioned to accelerate precise diagnosis and continue to build novel insights into the genetic factors causing rare diseases.

Neutral

Tranche Update on Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO)'s Equity Buyback Plan announced on March 25, 2021.

2021-11-03 13:09:00

From July 1, 2021 to September 30, 2021, the company has repurchased 5,306,184 shares, representing 8.86% for $254.38 million. With this, the company has completed the repurchase of 15,800,152 shares, representing 23.89% for $783.38 million under the buyback announced on March 25, 2021.

Neutral

Agios Pharmaceuticals, Inc. - Analyst/Investor Day

2021-11-03 11:10:00

To discuss the company’s research and development pipeline, as well as provide additional insights into the commercial launch strategy and expectations for mitapivat in PK deficiency

Neutral

Agios Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 03, 2021

2021-10-21 20:01:00

Agios Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Agios Pharmaceuticals, Inc. Presents at 10th Annual Sickle Cell Disease Therapeutics Conference, Sep-15-2021 01:50 PM

2021-09-15 13:42:00

Agios Pharmaceuticals, Inc. Presents at 10th Annual Sickle Cell Disease Therapeutics Conference, Sep-15-2021 01:50 PM. Speakers: Sarah Gheuens, Chief Medical Officer.

Neutral

Global Blood Therapeutics, Inc., Sickle Cell Disease Association of America, Inc., 10th Annual Sickle Cell Disease Therapeutics Conference, Sep 15, 2021

2021-09-08 21:05:00

Global Blood Therapeutics, Inc., Sickle Cell Disease Association of America, Inc., 10th Annual Sickle Cell Disease Therapeutics Conference, Sep 15, 2021.

Neutral

Agios Pharmaceuticals, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-10-2021 12:30 PM

2021-08-30 11:00:00

Agios Pharmaceuticals, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-10-2021 12:30 PM. Venue: New York, United States. Speakers: Jackie Fouse, CEO.

Neutral

Agios Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 08:00 AM

2021-08-30 11:00:00

Agios Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 08:00 AM. Venue: New York, United States. Speakers: Darrin Miles, Chief Commercial Officer, Jessica Rennekamp, Associate Director of Corporate Communications, Jonathan Biller, CFO and Head of Legal & Corporate Affairs, Sarah Gheuens, Chief Medical Officer.

Neutral

Sickle Cell Advocacy, 8th Annual Sickle Cell Warriors Convention, Aug 25, 2021 through Aug 29, 2021

2021-08-20 12:44:00

Sickle Cell Advocacy, 8th Annual Sickle Cell Warriors Convention, Aug 25, 2021 through Aug 29, 2021.

Positive

Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

2021-08-17 20:01:00

Agios Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for mitapivat for the treatment of adults with pyruvate kinase (PK) deficiency. The NDA was granted a Priority Review designation and has been given a Prescription Drug User Fee Act (PDUFA) action date of February 17, 2022, accelerating the review time from 10 months to six months from the day of filing acceptance. The FDA’s Priority Review designation is given to investigational medicines that treat a serious condition and offer significant improvements in safety or effectiveness. Agios also submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) in June 2021 for mitapivat as a potential treatment for adults with PK deficiency. As announced on the company’s second quarter 2021 earnings call, the MAA passed validation which triggered the start of the MAA review procedure. The NDA and MAA submissions are based on results from two pivotal studies, ACTIVATE and ACTIVATE-T, conducted in not regularly transfused and regularly transfused adults with PK deficiency, respectively. A full analysis of these data – including patient-reported outcomes (PRO) – was recently presented at the European Hematology Association (EHA) Virtual Congress. An extension study for adults with PK deficiency previously enrolled in ACTIVATE or ACTIVATE-T is ongoing and designed to evaluate the long-term safety, tolerability and efficacy of treatment with mitapivat. Mitapivat is not currently approved for use in any country.

Negative

Agios Pharmaceuticals, Inc. Announces Executive Changes

2021-08-04 20:36:00

On August 1, 2021, Agios Pharmaceuticals, Inc. (the 'Company') appointed T.J. Washburn, senior director, corporate accounting of the Company, to serve as the Company’s principal accounting officer. Mr. Washburn, age 40, has nearly 20 years of technical accounting, financial reporting and corporate accounting experience, spending the last 4 years in positions of increasing responsibility at the Company. Prior to joining the Company, Mr. Washburn served in financial and corporate accounting roles at Ernst & Young, Cubist Pharmaceuticals (prior to its acquisition by Merck & Co.), Raytheon, Rue La La and Pricewaterhouse Coopers. Mr. Washburn is a certified public accountant, and obtained his bachelor of science degree in business administration from Babson College.

Neutral

American Society Of Hematology, 63rd American Society of Hematologists Annual Meeting & Exposition, Dec 11, 2021 through Dec 15, 2021

2021-07-31 11:04:00

American Society Of Hematology, 63rd American Society of Hematologists Annual Meeting & Exposition, Dec 11, 2021 through Dec 15, 2021. Venue: Georgia World Congress Center, Atlanta, Georgia, United States.

Negative

Agios Pharmaceuticals, Inc. Announces Executive Changes

2021-07-29 11:00:00

Agios Pharmaceuticals, Inc. announced succession plan for Chris Bowden, M.D., who will transition from his role as chief medical officer to strategic advisor following his retirement on Sept. 1, at which time Sarah Gheuens, M.D., Ph.D., vice president of clinical development, will assume the role.

Neutral

Tranche Update on Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO)'s Equity Buyback Plan announced on March 25, 2021.

2021-07-29 10:57:00

From April 1, 2021 to June 30, 2021, the company has repurchased 10,493,968 shares, representing 15.03% for $529 million. With this, the company has completed the repurchase of 10,493,968 shares, representing 15.03% for $529 million under the buyback announced on March 25, 2021.

Neutral

Agios Pharmaceuticals, Inc. to Report Q2, 2021 Results on Jul 29, 2021

2021-07-27 21:27:00

Agios Pharmaceuticals, Inc. announced that they will report Q2, 2021 results on Jul 29, 2021

Neutral

Agios Pharmaceuticals, Inc., Q2 2021 Earnings Call, Jul 29, 2021

2021-07-15 11:00:00

Agios Pharmaceuticals, Inc., Q2 2021 Earnings Call, Jul 29, 2021

Fundamental Summary

When Agios Pharmaceuticals released its Q1 data on 2022-05-05, the results seemed positive but underwhelming. While their growth and income factors looked good, the overall picture didn't show outstanding numbers. Thus, Agios Pharmaceuticals received an overall score of 60, which translates to a HOLD recommendation.

Agios Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 0.832 million. Net loss was USD 94.77 million compared to net income of USD 1,874.33 million a year ago. Diluted loss per share from continuing operations was USD 1.74 compared to USD 1.31 a year ago.

Business Description

Agios Pharmaceuticals, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Sector Overview

Agios Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Agios Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 1,335.9 -7.1% 66
Liabilities 128.4 -11.9% 50
Price to Book 0.8 -41.0% 48
Cash & Equivalents 80.0 -60.6% 38
Equity 1,207.5 -6.5% 52
EBITDA -364.8 -2.9% 64
Total Revenues 0.8 -99.6% 99
Parameter Value Change Score
Return on Equity -20.6 51.2% 54
Net Cashflow -1,808.0 -2488.7% 85
Capital Expenditure -7.5 -31.2% 44
Asset Turnover 0.0 -99.7% 46
Free Cashflow -6.9 -1.1% 68

* All values are TTM

The below chart reflects Agios Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Agios Pharmaceuticals's peer average final assessment score stands on 59.0, Agios Pharmaceuticals's score is 60.

  •  AGIO
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 26 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 28 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 29 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 30 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 31 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 32 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Agios Pharmaceuticals's stock is now priced above its 5-day and 50-day, but below its 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in both the short and medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Agios Pharmaceuticals's stock indicates that it's likely oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 68.

Neutral 68
Close Price 22.61
52W Low 17.06
52W High 58.18
5D MA 21.64
50D MA 21.2
200D MA 32.4
MACD 0.11
RSI 21.62
STOCH 91.13

Balance Sheet Analysis

Agios Pharmaceuticals's balance sheet factors had several troubling metrics this period. Agios Pharmaceuticals's management did a relatively poor job managing cash and cash equivalents, which now sit at 80.0 and represents a -60.6% change from the last reporting period. The company's cash and cash equivalents metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their cash and cash equivalents with a score of 38. Also, Agios Pharmaceuticals publishes discouraging results related to book value factors in this report. As of the current filing, price to book ratio (P/B) was reported as 0.8, representing a -41.0% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. The company's book value factors were lackluster and showed that management hasn't figured out how to overperform expectations. Disappointing results in book value factors typically precede negative pressure in stock prices, so its book value factors received a grade of 48. However, one encouraging metric, Assets, stood out. Agios Pharmaceuticals's management was effective in managing the value of the assets on their balance sheet, which now sits at 1335.9 and represents a -7.1% change from the previous report. This performance is interesting in comparison to its peers and competitors. Therefore, its asset component earned a score of 66. Consequently, their balance sheet earned a rank of 50.

Parameter Value Change Score
Assets 1,335.9 -7.1% 66
Liabilities 128.4 -11.9% 50
Price to Book 0.8 -41.0% 48
Cash & Equivalents 80.0 -60.6% 38
Equity 1,207.5 -6.5% 52
* All values are TTM

The below chart describes Agios Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Agios Pharmaceuticals received a balance sheet score of 50, the average of its peers stands on 60.0.

  •  AGIO
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 26 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 28 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 29 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 30 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 31 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 32 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Agios Pharmaceuticals appears likely to maintain its strong income statement metrics, especially Revenue Efficiency and EBITDA. Agios Pharmaceuticals did an excellent job managing its revenue efficiency this past period. Agios Pharmaceuticals's revenue efficiency is 0.8 according to the metrics in the current filing, which represents a -99.6% change from the previous report. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their industry-leading revenue efficiency makes a strong case for upward pressure on its's stock price. As a result, its revenue efficiency earned a score of 99. Also, Agios Pharmaceuticals reported impressive EBITDA this period. At filing, EBITDA was reported as -364.8, representing -2.9% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. The company's EBITDA movement, therefore, received a grade of 64. That said, one metric, Return Factors, stood out as strongly negative. In this filing, Agios Pharmaceuticals reported a return on equity (ROE) ratio of -20.6, which represents a growth of 51.2%. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. The company's return factor metrics return on equity and return on assets are even more concerning when compared to their peers. Its return factors (ROA & ROE) components, therefore, received a grade of 54. Consequently, the companie's income statement earned a rank of 75.

Parameter Value Change Score
EBITDA -364.8 -2.9% 64
Total Revenues 0.8 -99.6% 99
Return on Equity -20.6 51.2% 54
* All values are TTM

The below chart describes Agios Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Agios Pharmaceuticals received a income statement score of 75 , the average of its peers stands on 62.0.

  •  AGIO
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 26 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 28 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 29 1
IVERIC bio, Inc. 1.1B 84 58 79 70 30 1
FibroGen, Inc. 1.0B 48 74 63 67 31 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 32 1
ImmunoGen, Inc. 946.1M 40 73 71 64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Agios Pharmaceuticals appears likely to maintain its strong cash flow metrics and momentum going forward. Agios Pharmaceuticals's management was effective in improving their net cash flow, which now sits at -1808.0 and represents a -2488.7% change from the previous report. Their net cash flow metrics are especially remarkable relative to their peers. The company's net cash flow, therefore, received a grade of 85. Also, Free cash flow numbers published by Agios Pharmaceuticals were -6.9, which was a -1.1% change from the previous filing. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. The company's free cash flow metrics are especially strong compared to its peers. Management seems to balance cash flow management, asset growth, and resource allocations in general. Consequently, their free cash flow movement received a grade of 68. At the same time, one critical cash flow metric, Capital Expenditure, was notably weak. Agios Pharmaceuticals's management did not a remarkable job this period managing capital expenditures (CapEx). In terms of the raw numbers, CapEx was reported as -7.5, which represents a -31.2% change from the last period. The company's disappointing CapEx growth is expected to stunt the momentum they hoped for this period. Its CapEx movement, therefore, received a grade of 44. Because the company's management is doing an excellent job managing these critical metrics, the cash flow was given a score of 75.

Parameter Value Change Score
Net Cashflow -1,808.0 -2488.7% 85
Capital Expenditure -7.5 -31.2% 44
Asset Turnover 0.0 -99.7% 46
Free Cashflow -6.9 -1.1% 68
* All values are TTM

The below chart describes Agios Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Agios Pharmaceuticals received a cash flow score of 75, the average of its peers stands on 67.0.

  •  AGIO
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 26 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 28 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 29 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 30 1
FibroGen, Inc. 1.0B 86 74 48 87 84 31 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 32 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.